Clinical trial
A Phase I Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety in Healthy Subjects with Multiple Administration of Tiprogrel
NCT06584812 is registered in ClinicalTrials.gov with Tianjin Institute of Pharmaceutical Research Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety in Healthy Subjects with Multiple Administration of Tiprogrel
- Lead sponsor
- Tianjin Institute of Pharmaceutical Research Co., Ltd
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 9, 2024
- Completion date
- December 17, 2024
- Enrollment
- 14 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.